Hikma Pharmaceuticals PLC HIK shares shed 3.16% to £19.02 Friday, on what proved to be an all-around rough trading session ...

Shares of Hikma Pharmaceuticals PLC HIK inched down 0.05% to £19.14 Wednesday, on what proved to be an all-around rough ...

The FDA approved generic versions of Vyvanse from 11 drugmakers, including U.S.-based drugmakers Mallinckrodt and Viatris, UK-based Hikma Pharmaceuticals, and Indian drugmaker Sun Pharmaceutical ...

On the downside, Hikma Pharmaceuticals slipped by 0.6%, reversing earlier gains that followed an upgrade to 'buy' from 'hold' by Berenberg. Rightmove dropped 5.03%, retreating after Monday's surge.

Barclays cuts Prudential price target to 1,250 (1,380) pence - 'overweight' Barclays reinitiates Barratt Developments with 'overweight' - price target 641 pence Barclays raises HGCapital Trust to ...

Hikma is offering clindamycin in 5% dextrose injection, in 300mg/50ml, 600mg/50ml and 900mg/50ml doses. The product is available in a vial. Clindamycin in 5% dextrose injection is indicated for ...

New Delhi: To maintain dominance in the global pharmaceutical market and bridge the gap between established and emerging players, Union Minister Jitin Prasada has urged the country’s ...

In this article, we are going to take a look at where Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stands against the other medical AI companies. Generally, when you hear the term "artificial ...

Also Read: Why Is Jazz Pharmaceuticals Stock Trading Lower ... and emphasized that other narcolepsy treatments are available. Hikma’s generic version of Xyrem only reached the market last ...

GMP can help pharmaceutical product designers to plan, execute, and document the product development process in a systematic and transparent way. By following GMP, designers can ensure that the ...